Biocon scales record high after turnaround Q2 outcome

Biocon rose 2.79% to Rs 1,007.60 at 10:45 IST on BSE after the company reported consolidated net profit of Rs 146.70 crore in Q2 September 2016 as compared with net loss of Rs 10.60 crore in Q2 September 2015.

The result was announced after market hours yesterday, 20 October 2016.

Meanwhile, the S&P BSE Sensex was down 138 points or 0.49% at 27,991.84

On BSE, so far 2.23 lakh shares were traded in the counter as against average daily volume of 1.67 lakh shares in the past one quarter. The stock hit a high of Rs 1,020 so far during the day, which is also a record high for the stock. The stock hit a low of Rs 978 so far during the day. The stock had hit a 52-week low of Rs 430.80 on 12 February 2016. The stock had outperformed the market over the past 30 days till 20 October 2016, gaining 3.48% compared with 1.32% fall in the Sensex. The scrip also outperformed the market in past one quarter, advancing 21.21% as against Sensex's 1.17% rise.

The large-cap company has equity capital of Rs 100 crore. Face value per share is Rs 5.

Biocon's consolidated total income rose 21.2% to Rs 992.50 crore in Q2 September 2016 over Q2 September 2015. Consolidated earnings before interest, taxation, depreciation and amortization (EBITDA) rose 45% to Rs 277 crore in Q2 September 2016 over Q2 September 2015. EBITDA margin improved to 28% in Q2 September 2016 from 23% in Q2 September 2015.

Biocon said that the company reported robust performance led by a strong growth of Small Molecules, Biologics and Syngene. Licensing income stood at Rs 32 crore while other income reported was Rs 52 crore in Q2 September 2016.

Commenting on the quarterly performance and highlights, Chairperson and Managing Director, Kiran Mazumdar-Shaw stated that the company's performance in Q2 September 2016, was led by strong growth across small molecules, biologics and research services. Expansion of biologics footprint in emerging markets and licensing agreements boosted the revenue further. The company's ready-to-use Insulin Glargine pen launched in Japan has been well received which augurs well for business. The acceptance of proposed biosimilar Trastuzumab filing for review by EMA was a critical milestone in Q2 September 2016. She added that long term investments in R&D, manufacturing facility in Malaysia and clinical advancement of programs will enable the company to unlock greater value, going forward.

Biocon is India's largest and fully-integrated, innovation-led biopharmaceutical company.

Powered by Capital Market - Live News